Allen et al. |
2011 |
Agitated patients with schizophrenia |
Phase II, randomized, double-blind, placebo-controlled study |
129 |
To evaluate inhaled loxapine for acute treatment of agitation in schizophrenia |
Single inhalation of 5 or 10 mg of loxapine or placebo |
Inhaled loxapine was generally safe and well tolerated and produced rapid improvement in agitated patients with psychotic disorders |
Lesem et al. |
2011 |
Agitated patients with schizophrenia |
Phase III, randomised, double-blind, placebo-controlled, parallel-group study |
344 |
To evaluate inhaled loxapine for acute treatment of agitation in schizophrenia |
Two or three doses of inhaled loxapine (5 or 10 mg) or placebo |
Inhaled loxapine was a well-tolerated and effective treatment of agitation in schizophrenia |
Kwentus et al. |
2012 |
Agitated patients with bipolar I disorder |
Phase III, randomized, double blind, placebo-controlled, parallel group inpatient study |
314 |
To evaluate inhaled loxapine for the acute treatment of agitation in patients with bipolar I disorder |
Inhaled loxapine 5 mg or 10 mg or inhaled placebo |
Inhaled loxapine provided a rapid, non-injection, well-tolerated acute treatment for agitation in patients with bipolar I disorder |
Krüger et al. |
2015 |
Agitated patients with borderline personality disorder |
Case series |
5 |
To evaluate inhaled loxapine for emergency treatment of agitated patients with borderline personality disorder |
Inhaled loxapine 10 mg |
Inhaled loxapine was safe, well tolerated and produced rapid improvement in agitated patients with borderline personality disorder |
Roncero et al. |
2016 |
Patients with dual diagnosis |
Retrospective case Series |
14 |
Efficacy of inhaled loxapine on episodes of psychotic agitation in patients with dual diagnosis |
Inhaled loxapine 10 mg |
Inhaled loxapine was rapid, effective, and well accepted in all dual-diagnosis patients presenting with acute agitation in the emergency setting |